BR9406821A - Peptideo sintético composiçao imunogenica kit de diagnostico útil para dectar anticorpos especificos de hiv em amostra de teste kit de diagnostico para detectar antigenos de hiv em amostra de teste codificaçao de molécula de ácido nucléico e anticorpo - Google Patents
Peptideo sintético composiçao imunogenica kit de diagnostico útil para dectar anticorpos especificos de hiv em amostra de teste kit de diagnostico para detectar antigenos de hiv em amostra de teste codificaçao de molécula de ácido nucléico e anticorpoInfo
- Publication number
- BR9406821A BR9406821A BR9406821A BR9406821A BR9406821A BR 9406821 A BR9406821 A BR 9406821A BR 9406821 A BR9406821 A BR 9406821A BR 9406821 A BR9406821 A BR 9406821A BR 9406821 A BR9406821 A BR 9406821A
- Authority
- BR
- Brazil
- Prior art keywords
- test sample
- diagnostic kit
- detecting hiv
- antibody
- nucleic acid
- Prior art date
Links
- 238000009007 Diagnostic Kit Methods 0.000 title 2
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 230000002163 immunogen Effects 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/802—Virus-based particle
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
- Y10S977/917—Vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/92—Detection of biochemical
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7337893A | 1993-06-09 | 1993-06-09 | |
PCT/CA1994/000317 WO1994029339A1 (en) | 1993-06-09 | 1994-06-08 | Tandem synthetic hiv-1 peptides |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9406821A true BR9406821A (pt) | 1996-03-26 |
Family
ID=22113349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9406821A BR9406821A (pt) | 1993-06-09 | 1994-06-08 | Peptideo sintético composiçao imunogenica kit de diagnostico útil para dectar anticorpos especificos de hiv em amostra de teste kit de diagnostico para detectar antigenos de hiv em amostra de teste codificaçao de molécula de ácido nucléico e anticorpo |
Country Status (10)
Country | Link |
---|---|
US (7) | US5639854A (pt) |
EP (1) | EP0702693A1 (pt) |
JP (1) | JPH08511007A (pt) |
KR (1) | KR960703136A (pt) |
CN (1) | CN1111540C (pt) |
AU (1) | AU693098B2 (pt) |
BR (1) | BR9406821A (pt) |
CA (1) | CA2164818C (pt) |
RU (1) | RU2201421C2 (pt) |
WO (1) | WO1994029339A1 (pt) |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5863542A (en) * | 1991-03-07 | 1999-01-26 | Virogenetics Corporation | Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts |
DE4420742A1 (de) * | 1993-10-20 | 1995-04-27 | Boehringer Mannheim Gmbh | Synthetischer Standard für Immunoassays |
DE4402756A1 (de) * | 1994-01-31 | 1995-08-03 | Boehringer Mannheim Gmbh | Spezifische Bindungssubstanzen für Antikörper und deren Verwendung für Immunoassays oder Vakzine |
AUPM885194A0 (en) * | 1994-10-14 | 1994-11-10 | Council Of The Queensland Institute Of Medical Research, The | Synthetic peptides and vaccines comprising same |
FR2731225B1 (fr) * | 1995-03-03 | 2003-10-31 | Pasteur Institut | Peptides de glycoproteine transmembranaire d'enveloppe et de proteine de capside du retrovirus humain du type hiv-1 et peptides presentant avec eux une parente immunologique |
EP1849869A3 (fr) | 1994-10-20 | 2011-05-18 | Institut Pasteur | Séquences nucléotidiques d'antigènes rétroviraux VIH-1 groupe (ou sous-groupe) 0 |
JPH11506336A (ja) * | 1995-06-07 | 1999-06-08 | コノート ラボラトリーズ リミテッド | 免疫系選択細胞への抗原送達のためのキメラ抗体 |
ATE395422T1 (de) | 1995-06-07 | 2008-05-15 | Sanofi Pasteur Ltd | Chimäre antikörper zur abgabe von antigenen an selektierte zellen des immunsystems |
AU746759B2 (en) * | 1997-08-28 | 2002-05-02 | Biomira Inc. | Randomly generated glycopeptide combinatorial libraries |
US5972339A (en) * | 1997-11-13 | 1999-10-26 | The General Hospital Corporation | Method of eliciting anti-HIV-1 helper T cell responses |
US6121021A (en) * | 1997-12-16 | 2000-09-19 | Connaught Laboratories Limited | Constitutive expression of non-infectious HIV-like particles |
US7105164B1 (en) | 1998-04-07 | 2006-09-12 | Sanofi Pasteur Limited | HIV-specific cytotoxic T-cell responses |
NZ508812A (en) * | 1998-06-12 | 2002-11-26 | Aventis Pasteur | Peptides for the prevention or treatment of HIV |
EP1141313A2 (en) | 1998-12-31 | 2001-10-10 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
US7935805B1 (en) * | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
AU2596600A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Modified hiv env polypeptides |
CA2358385C (en) | 1998-12-31 | 2013-08-06 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
US6395714B1 (en) | 1999-02-24 | 2002-05-28 | Aventis Pasteur Limited | Expressing gp140 fragment of primary HIV-1 isolate |
AU3412500A (en) * | 1999-03-25 | 2000-10-16 | Agene Research Institute Co., Ltd. | Lipid-based artificial particles inducing cell-mediated immunity |
US6737066B1 (en) * | 1999-05-06 | 2004-05-18 | The Immune Response Corporation | HIV immunogenic compositions and methods |
US6712812B2 (en) | 1999-08-05 | 2004-03-30 | Broncus Technologies, Inc. | Devices for creating collateral channels |
EP1400204A1 (en) | 1999-08-05 | 2004-03-24 | Broncus Technologies, Inc. | Methods and devices for creating collateral channels in the lungs |
US7175644B2 (en) * | 2001-02-14 | 2007-02-13 | Broncus Technologies, Inc. | Devices and methods for maintaining collateral channels in tissue |
US7815590B2 (en) | 1999-08-05 | 2010-10-19 | Broncus Technologies, Inc. | Devices for maintaining patency of surgically created channels in tissue |
US6749606B2 (en) | 1999-08-05 | 2004-06-15 | Thomas Keast | Devices for creating collateral channels |
EP1088889A1 (en) * | 1999-10-01 | 2001-04-04 | University Of Cambridge | Recombinant double hybrid filamentous bacteriophage |
WO2001047955A2 (en) * | 1999-12-23 | 2001-07-05 | Medical Research Council | Improvements in or relating to immune responses to hiv |
US6982086B2 (en) | 2000-02-04 | 2006-01-03 | Duke University | Human immunodeficiency virus immunogenic composition |
DK1280551T3 (da) * | 2000-04-27 | 2007-05-21 | Sanofi Pasteur Ltd | Vacciner mod HIV-infektion |
AUPQ776100A0 (en) * | 2000-05-26 | 2000-06-15 | Australian National University, The | Synthetic molecules and uses therefor |
CN1172717C (zh) * | 2000-08-18 | 2004-10-27 | 清华大学 | 一种治疗艾滋病的药物及其制备方法 |
US7083787B2 (en) * | 2000-11-15 | 2006-08-01 | Globeimmune, Inc. | Yeast-dendritic cell vaccines and uses thereof |
DE10106295C1 (de) * | 2001-02-02 | 2002-08-22 | Gaifar German American Inst Fo | Protein mit mehreren Antigen-Epitop-Sequenzen, welches immobilisiert ist |
EP1411770A4 (en) | 2001-07-05 | 2006-05-10 | Chiron Corp | POLYNUCLEOTIDES CODING FOR ANTIGENIC C-TYPE HIV POLYPEPTIDES, POLYPEPTIDES AND THEIR USE |
EP2280074A3 (en) | 2001-07-05 | 2011-06-22 | Novartis Vaccines and Diagnostics, Inc. | Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof |
US20030185858A1 (en) * | 2001-08-15 | 2003-10-02 | Birkett Ashley J. | Immunogenic HBc chimer particles stabilized with an N-terminal cysteine |
WO2003020876A2 (en) * | 2001-08-31 | 2003-03-13 | Chiron Corporation | Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof |
US7708712B2 (en) | 2001-09-04 | 2010-05-04 | Broncus Technologies, Inc. | Methods and devices for maintaining patency of surgically created channels in a body organ |
ES2274100T3 (es) * | 2001-09-07 | 2007-05-16 | Polymun Scientific Immunbiologische Forschung Gmbh | Anticuerpos que reconocen a un peptido que imita a un epitopo criptico de gp41 del vih-1. |
AU2002363436A1 (en) * | 2001-11-07 | 2003-05-19 | Duke University | Polyvalent immunogen of hiv |
US7195768B2 (en) * | 2001-11-07 | 2007-03-27 | Duke University | Polyvalent immunogen |
US7172761B2 (en) * | 2001-11-07 | 2007-02-06 | Duke University | Polyvalent immunogen |
US20030125518A1 (en) * | 2001-12-01 | 2003-07-03 | Crevecoeur Harry F. | Surface simulation synthetic peptides useful in the treatment of hyper-variable viral pathogens |
US7553926B2 (en) * | 2002-04-23 | 2009-06-30 | Andrea Savarino | Compositions containing anti-HIV peptides and methods for use |
US20030224121A1 (en) * | 2002-05-29 | 2003-12-04 | David Karroll | Paint applicator |
CN1472314A (zh) * | 2002-07-29 | 2004-02-04 | 清华大学 | 艾滋病病毒o型株的一个免疫学表位及其应用 |
GB0228939D0 (en) * | 2002-12-12 | 2003-01-15 | Univ Nottingham | Peptide presentations for human immunodeficiency disease vaccines |
FR2850106B1 (fr) | 2003-01-17 | 2005-02-25 | Aventis Pasteur | Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5 |
WO2004091491A2 (en) * | 2003-04-10 | 2004-10-28 | Transform Pharmaceuticals, Inc. | Profiling conformational variants, antibody compositions and methods of using the same |
JP2007531705A (ja) * | 2003-05-20 | 2007-11-08 | セルペップ ソシエテ アノニム | 増大した活性および細胞膜親和性を有する修飾抗ウイルス性ペプチド |
ATE480203T1 (de) * | 2003-05-27 | 2010-09-15 | Spinalmotion Inc | Bandscheibenprothese für die intervertebrale einführung |
US8002740B2 (en) | 2003-07-18 | 2011-08-23 | Broncus Technologies, Inc. | Devices for maintaining patency of surgically created channels in tissue |
US8308682B2 (en) | 2003-07-18 | 2012-11-13 | Broncus Medical Inc. | Devices for maintaining patency of surgically created channels in tissue |
US20070166784A1 (en) * | 2003-09-15 | 2007-07-19 | Barnett Susan W | Combination approaches for generating immune responses |
US7622125B2 (en) | 2004-05-05 | 2009-11-24 | Novartis Vaccines And Diagnostics, Inc. | Polycistronic HIV vector constructs |
US8409167B2 (en) | 2004-07-19 | 2013-04-02 | Broncus Medical Inc | Devices for delivering substances through an extra-anatomic opening created in an airway |
EP2266602A3 (en) | 2004-11-01 | 2011-08-10 | Novartis Vaccines and Diagnostics, Inc. | Combination approaches for generating immune responses |
GB0614755D0 (en) * | 2006-07-25 | 2006-09-06 | Univ Geneve | Cytokine derivatives |
EP2161279A1 (en) * | 2008-08-29 | 2010-03-10 | Centre National de la Recherche Scientifique | Synthetic peptides corresponding to overlapping neutralizing determinants in the CBD1 epitope induce broadly neutralizing antibodies |
EP2356133B1 (en) | 2008-10-10 | 2019-07-31 | Zera Intein Protein Solutions, S.L. | Recombinant protein bodies as immunogen-specific adjuvants |
EP2239569A1 (en) | 2009-04-09 | 2010-10-13 | Lophius Biosciences GmbH | Method for polypeptide transfer into cells |
AU2011230619C1 (en) | 2010-03-25 | 2016-06-23 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
EP2418284A1 (en) | 2010-08-13 | 2012-02-15 | ERA Biotech, S.A. | Protein body-inducing polypeptide sequences |
EP2706940B1 (en) | 2011-05-13 | 2016-12-14 | Broncus Medical, Inc. | Methods and devices for ablation of tissue |
US8709034B2 (en) | 2011-05-13 | 2014-04-29 | Broncus Medical Inc. | Methods and devices for diagnosing, monitoring, or treating medical conditions through an opening through an airway wall |
LT2691530T (lt) | 2011-06-10 | 2018-08-10 | Oregon Health & Science University | Cmv glikoproteinai ir rekombinantiniai vektoriai |
US20130189754A1 (en) | 2011-09-12 | 2013-07-25 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
EP2780035A1 (en) | 2011-11-14 | 2014-09-24 | Novartis AG | Immunogenic complexes of polyanionic carbomers and env polypeptides and methods of manufacture and use thereof |
WO2013078235A1 (en) | 2011-11-23 | 2013-05-30 | Broncus Medical Inc | Methods and devices for diagnosing, monitoring, or treating medical conditions through an opening through an airway wall |
EP2620446A1 (en) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
WO2013126622A1 (en) | 2012-02-24 | 2013-08-29 | President And Fellows Of Harvard College | Methods for displaying polypeptides and uses thereof |
EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
DK3007717T3 (da) | 2013-06-12 | 2019-01-02 | Pharis Biotec Gmbh | Peptider med antagonistiske aktiviteter mod naturlig cxcr4 |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
CN105709219B (zh) * | 2014-12-04 | 2019-12-20 | 复旦大学 | 一种基于对称构象免疫原的艾滋病疫苗及其制备方法 |
US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
CN110461261A (zh) | 2017-04-03 | 2019-11-15 | 堃博生物科技公司 | 电手术接入鞘 |
US20200102356A1 (en) * | 2018-10-01 | 2020-04-02 | NMC Inc. | Compositions and Methods for the Treatment of Huanglongbing (HLB) aka Citrus Greening in Citrus Plants |
AU2020384323A1 (en) | 2019-11-14 | 2022-06-02 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4925784A (en) * | 1986-04-04 | 1990-05-15 | Hoffmann-La Roche Inc. | Expression and purification of an HTLV-III gag/env gene protein |
US5081226A (en) * | 1986-12-30 | 1992-01-14 | The United States Of America As Represented By The Department Of Health And Human Services | Synthetic peptides sharing sequence homology with the HIV envelope protein |
US5229490A (en) * | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
US5019387A (en) * | 1987-09-08 | 1991-05-28 | Duke University | Production of antibodies to HIV |
EP0362910A3 (en) * | 1988-08-27 | 1991-01-09 | Akzo N.V. | Synthetic peptides immunochemically reactive with hiv-antibodies |
GB8910145D0 (en) * | 1989-05-03 | 1989-06-21 | Connaught Lab | Synthetic peptides for an hiv-1 vaccine |
FR2650954B1 (fr) * | 1989-08-18 | 1992-02-28 | Pasteur Institut | Composition resultant de la reunion d'un epitope b de la glycoproteine d'enveloppe d'un retrovirus du type iv et d'un epitope t issu d'une proteine distincte codee par ce retrovirus et leur application a la production d'anticorps protecteurs contre le sida |
DK0592546T3 (da) * | 1991-06-14 | 2003-09-15 | Us Gov Health & Human Serv | Immundeficiens-virus rekombinant poxvirus-vaccine |
ATE193208T1 (de) * | 1992-02-10 | 2000-06-15 | Univ Duke | Verwendung synthetischer peptide zur induktion der toleranz gegen t- und b-zell epitope von autoantigenen |
KR0172970B1 (ko) * | 1992-06-17 | 1999-02-01 | 김영길 | Aids백신에 유용한 키메릭 단백 및 그의 제조방법 |
WO1994016084A1 (en) * | 1993-01-16 | 1994-07-21 | British Bio-Technology Limited | Hybrid particle-forming protein comprising a particle-inducing segment and a plurality of antigens |
-
1994
- 1994-06-08 CN CN94192854A patent/CN1111540C/zh not_active Expired - Fee Related
- 1994-06-08 RU RU96102594/13A patent/RU2201421C2/ru not_active IP Right Cessation
- 1994-06-08 KR KR1019950705602A patent/KR960703136A/ko not_active IP Right Cessation
- 1994-06-08 AU AU69673/94A patent/AU693098B2/en not_active Ceased
- 1994-06-08 EP EP94918258A patent/EP0702693A1/en not_active Ceased
- 1994-06-08 BR BR9406821A patent/BR9406821A/pt not_active Application Discontinuation
- 1994-06-08 CA CA002164818A patent/CA2164818C/en not_active Expired - Lifetime
- 1994-06-08 JP JP7501144A patent/JPH08511007A/ja active Pending
- 1994-06-08 WO PCT/CA1994/000317 patent/WO1994029339A1/en not_active Application Discontinuation
- 1994-06-09 US US08/257,528 patent/US5639854A/en not_active Expired - Lifetime
-
1995
- 1995-06-02 US US08/460,602 patent/US5759769A/en not_active Expired - Lifetime
- 1995-06-05 US US08/465,217 patent/US5800822A/en not_active Expired - Lifetime
- 1995-06-05 US US08/463,966 patent/US5795955A/en not_active Expired - Lifetime
- 1995-06-05 US US08/462,507 patent/US5876731A/en not_active Expired - Lifetime
- 1995-06-05 US US08/464,329 patent/US5817754A/en not_active Expired - Lifetime
- 1995-06-06 US US08/467,881 patent/US5951986A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
AU693098B2 (en) | 1998-06-25 |
CN1128538A (zh) | 1996-08-07 |
US5795955A (en) | 1998-08-18 |
KR960703136A (ko) | 1996-06-19 |
US5800822A (en) | 1998-09-01 |
RU2201421C2 (ru) | 2003-03-27 |
CN1111540C (zh) | 2003-06-18 |
US5639854A (en) | 1997-06-17 |
US5759769A (en) | 1998-06-02 |
US5951986A (en) | 1999-09-14 |
CA2164818C (en) | 2003-09-23 |
CA2164818A1 (en) | 1994-12-22 |
US5876731A (en) | 1999-03-02 |
WO1994029339A1 (en) | 1994-12-22 |
JPH08511007A (ja) | 1996-11-19 |
EP0702693A1 (en) | 1996-03-27 |
AU6967394A (en) | 1995-01-03 |
US5817754A (en) | 1998-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9406821A (pt) | Peptideo sintético composiçao imunogenica kit de diagnostico útil para dectar anticorpos especificos de hiv em amostra de teste kit de diagnostico para detectar antigenos de hiv em amostra de teste codificaçao de molécula de ácido nucléico e anticorpo | |
BR8807567A (pt) | Teste imuno-enzimatico simultaneo para a deteccao de antigeno e/ou anticorpo em humanos | |
ES2068844T3 (es) | Dispositivo analitico en fase solida y metodo para su utilizacion. | |
PT100724A (pt) | Processo de determinacao da quantidade de grupos tiol ligados em proteinas e conjunto para a deteccao de estados isquemicos | |
ITMI942083A0 (it) | Strumento diagnostico automatizzato in particolare per l'analisi di campioni in pacchi di prova per un analita | |
ES2098256T3 (es) | Ensayo cinetico para la endotoxina utilizando lisado amebocitico de limulus y sustrato cromogenico. | |
NO901899D0 (no) | Hiv-peptider, syntetiske hiv-antigener og immunoanalysekit | |
ATE125572T1 (de) | Immunodiagnostisches verfahren zum nachweis und zur bestimmung von euterentzündung. | |
CA2007336A1 (en) | Diagnostic test using chimeric antibodies | |
EP0383313A3 (en) | Reagent for immunoassay, and kit containing the same | |
CA2193323A1 (en) | Process for preparing a synthetic calibrator for use in sandwich immunoassays, which calibrator consists of an antibody against one of the antibodies used in the assay and of a sequence of the analyte | |
CA2385830A1 (en) | Probe for protein-protein interaction analysis, and method of using it for analysis of protein-protein interaction | |
WO2003046140A3 (en) | Immunoassay and kit for an early and simulataneous detection of biochemical markers in a patient's sample | |
EP0869177A3 (en) | Human a- and b- platelet-derived growth factor receptor proteins and uses therefor. | |
DE69942215D1 (de) | Verfahren zum immunochemischen Testen des Anti-HM1.24-Antikörpers | |
ES2177547T3 (es) | Metodo gradual para detectar la enfermedad de chagas y reactivos utilizados en tales efectos. | |
KR880014376A (ko) | Hiv 특이 항원 영역의 모노클로날 항체 및 그 용법 | |
HUP9904222A2 (hu) | Eljárás p53 elleni antitestek kimutatására | |
ATE293792T1 (de) | Eine methode zur messung der konzentration eines antigens | |
KR930700548A (ko) | 자궁내막 항체 측정방법 및 측정용 자궁내막 항원, 조성물, 테스트킷 | |
ES2131279T3 (es) | Inmunoensayo de tipo sandwich para n-peptido. | |
DE10190630D2 (de) | Verfahren zum Nachweis von Helicobacter Pylori und Heilmanii in Stuhl- und Speichelproben und Biopsiematerial | |
DE3686717D1 (de) | Immuntestverfahren. | |
ES2056074T3 (es) | Procedimiento inmunoquimico y reactivo para la determinacion de un antigeno polivalente en una muestra liquida. | |
BR9508748A (pt) | Peptídeo uso do mesmo anticorpos linhagens de células linhagem de célula de hibridoma composição farmacêutica vacina contraceptiva processo para detectar anticorpos auto-imunes no soro de um paciente estojo de teste e reagente diagnóstico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EG | Technical examination (opinion): publication of technical examination (opinion) | ||
ND | Extension of time allowed | ||
FC | Decision: refusal | ||
B15K | Others concerning applications: alteration of classification |
Ipc: C07K 14/005 (2006.01), G01N 33/569 (2006.0 |